Images from the world's largest radiology conference include new technologies and the latest advances in MRI, CT, nuclear medicine, X-ray, artificial intelligence, and PACS/enterprise imaging.

Outdated infrastructure and a lack of young people entering the field are both impacting the security of critical isotopes such as molybdenum-99.

The Biograph Vision.X is able to deliver an estimated 20% performance improvement, bolstering throughput while reducing radiotracer costs. 

Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more. 

Nucleus RadioPharma will use the money to establish manufacturing facilities—with one located in Rochester, Minnesota, near Mayo—and build new technology for distribution.

Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Eliminating the previous “coverage with evidence development” requirement allows local MACs to dictate payment for such exams. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview.